Cargando…

M213. COMPARISON OF LONG-TERM ANTIPSYCHOTIC USE DATA FROM MEDICAL RECORDS AND NATIONAL PRESCRIPTION REGISTER

Abstract not included.

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Poster Session II
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7234664/ http://dx.doi.org/10.1093/schbul/sbaa030.525

Ejemplares similares

M148. NORMALIZATION IN REWARD PROCESSING DURING INITIAL TREATMENT MAY PREDICT LONG-TERM CLINICAL OUTCOME IN ANTIPSYCHOTIC NAïVE SCHIZOPHRENIA PATIENTS
por: Nielsen, Mette, et al.
Publicado: (2020)

M47. AKATHISIA AND ATYPICAL ANTIPSYCHOTICS: EXPLORING ASSOCIATIONS TO SUICIDALITY AND AGITATION
por: Bjarke, Jill, et al.
Publicado: (2020)

M172. POLYGENIC RISK SCORES ANALYSES IN ANTIPSYCHOTIC-INDUCED WEIGHT GAIN
por: Yoshida, Kazunari, et al.
Publicado: (2020)

M203. ANTIPSYCHOTIC-LIKE EFFECT OF DOXYCYCLINE IN PSYCHOTOMIMETICS SYMPTOMS INDUCED BY AMPHETAMINE
Publicado: (2020)

T213. TREND OF LONG-ACTING INJECTABLE ANTIPSYCHOTICS USE IN ASIA: FINDINGS FROM REAP ANTIPSYCHOTIC STUDIES
por: Lin, Shih-Ku, et al.
Publicado: (2020)

M157. A MULTICENTRE STUDY OF 1H-MRS BRAIN GLUTAMATE LEVELS IN SCHIZOPHRENIA; INVESTIGATING THE EFFECT OF ANTIPSYCHOTIC MEDICATION, SYMPTOM SEVERITY AND AGE
por: Merritt, Kate, et al.
Publicado: (2020)

M60. EARLY VERSUS DELAYED PRESCRIPTION OF CLOZAPINE AND THE COGNITIVE PERFORMANCE ON SCHIZOPHRENIA
por: Amoretti, Silvia, et al.
Publicado: (2020)

M105. ACTIGRAPHIC MONITORING OF SLEEP-WAKE CYCLE IN SCHIZOPHRENIA OUTPATIENTS RECEIVING A LONG-ACTING INJECTABLE ANTIPSYCHOTIC: FEASIBILITY AND INITIAL RESULTS FROM A PROSPECTIVE RCT
por: Yagoda, Sergey, et al.
Publicado: (2020)

M197. SEASONAL ANTIPSYCHOTICS IN SCHIZOPHRENIA: OUTCOMES IN NATURALISTIC SETTINGS (SEASONS STUDY) OBSERVATIONAL RETROSPECTIVE MULTICENTRE CANADIAN STUDY ON 3MONTH-FORMULATION OF LONG-ACTING INJECTABLE PALIPERIDONE PALMITATE
por: Corbeil, Olivier, et al.
Publicado: (2020)

M199. COPY NUMBER VARIANCE (CNV) ANALYSIS TO DETERMINE OPTIMAL ANTIPSYCHOTIC DOSAGE IN SCHIZOPHRENIA: A PILOT STUDY
por: Adanty, Christopher, et al.
Publicado: (2020)

M77. USE OF TESTING TO IMPROVE LONG-TERM MEMORY RECALL IN PEOPLE WITH PSYCHOSIS
por: Daniel Ragland, J, et al.
Publicado: (2020)

M169. HIPPOCAMPAL GLUTAMATE AND HIPPOCAMPUS SUBFIELD VOLUMES IN ANTIPSYCHOTIC-NAIVE FIRST EPISODE PSYCHOSIS SUBJECTS AND RELATIONSHIPS TO DURATION OF UNTREATED PSYCHOSIS
Publicado: (2020)

M205. LONG-TERM SAFETY OF LUMATEPERONE (ITI-007): METABOLIC EFFECTS IN A 1-YEAR STUDY
por: Satlin, Andrew, et al.
Publicado: (2020)

M143. REGIONAL CEREBRAL BLOOD FLOW IN INITIALLY ANTIPSYCHOTIC-NAïVE PATIENTS WITH SCHIZOPHRENIA OR PSYCHOSIS: EFFECTS OF PARTIAL D2 RECEPTOR AGONISM AND ASSOCIATION WITH SYMPTOM IMPROVEMENT
por: Bojesen, Kirsten, et al.
Publicado: (2020)

M22. IGG ANTIBODIES TO TOXOPLASMA GONDII ARE ASSOCIATED WITH INCREASED LONG-TERM RISK FOR PSYCHOSIS IN INDIVIDUALS AT ULTRA-HIGH RISK FOR PSYCHOSIS
por: Berger, Maximus, et al.
Publicado: (2020)

M209. TO WHOM WE PRESCRIBE LONG ACTING ANTPSYCHOTICS AT DISCHARGE FROM HOSPITAL?
por: Ucok, Alp, et al.
Publicado: (2020)

M217. EFFICACY OF PALIPERIDONE PALMITATE ON PSYCHIATRIC SYMPTOMS AND ATTITUDES TOWARD MEDICATION IN SCHIZOPHRENIA
Publicado: (2020)

M130. COMPARISON OF CUMULATIVE INCIDENCE OF HOSPITAL TREATED PSYCHOSIS IN FIVE FINNISH BIRTH COHORTS
por: Kerkelä, Martta, et al.
Publicado: (2020)

M87. PREVALENCE OF AUTOIMMUNE DISEASES IN INDIVIDUALS WITH PRIMARY PSYCHOTIC DISORDERS AT BOSTON MEDICAL CENTER
por: Brown, Kayla, et al.
Publicado: (2020)

M125. DISEASE PREVALENCE, COMORBID CONDITIONS, AND MEDICATION UTILIZATION AMONG PATIENTS WITH SCHIZOPHRENIA IN THE UNITED STATES
por: Roy, Brittany, et al.
Publicado: (2020)

M152. IS MEDICAL SERVICES UTILISATION A MODERATING FACTOR OF EARLY EXCESS MORTALITY IN PATIENTS WITH SCHIZOPHRENIA
por: Krivoy, Amir, et al.
Publicado: (2020)

M49. BEHAVIOURAL SOCIAL COGNITION IN SCHIZOPHRENIA SPECTRUM DISORDERS IN COMPARISON TO AUTISM SPECTRUM DISORDER: A SYSTEMATIC REVIEW AND META-ANALYSIS
por: Oliver, Lindsay, et al.
Publicado: (2020)

M99. INVESTIGATING THE BEST PREDICTIVE CLINICAL FEATURES OF ANTI-N-METHYL-D-ASPARTATE RECEPTOR (NMDAR) ENCEPHALITIS IN THE 2010 AUSTRALIAN NATIONAL SURVEY OF HIGH IMPACT PSYCHOSIS (SHIP) COHORT
por: Rossell, Susan, et al.
Publicado: (2020)

M242. PREDICTORS OF CRIMINAL SENTIMENTS SCALE (CSS-M) SCORES AMONG OUTPATIENTS WITH PSYCHOTIC DISORDERS
por: Zern, Adria, et al.
Publicado: (2020)

M73. DRIVING ABILITIES IN PATIENTS WITH SCHIZOPHRENIA
por: Pardeller, Silvia, et al.
Publicado: (2020)

M190. USE OF NULL PRONOUNS IN SCHIZOPHRENIA
por: Chaves, Monica, et al.
Publicado: (2020)

M168. CLINICAL-ANATOMICAL PHENOTYPES OF SCHIZOPHRENIA
por: Kirschner, Matthias, et al.
Publicado: (2020)

M109. WEIGHT GAIN AND THE PATHOPHYSIOLOGY OF SCHIZOPHRENIA
Publicado: (2020)

M133. DISCRIMINATION PHENOMENA AND THE LEVEL OF SCHIZOTYPY
por: Pignon, Baptiste, et al.
Publicado: (2020)

M64. ADDRESSING THE ROLE OF TIMING ON COGNITION IN SCHIZOPHRENIA
por: Alústiza, Irene, et al.
Publicado: (2020)

M117. ELUCIDATING ARCHITECTURE OF NEGATIVE SYNDROME IN SCHIZOPHRENIA
por: San Ang, Mei, et al.
Publicado: (2020)

M245. AN RCT PROTOCOL OF HYBRID-ECT FOR SCHIZOPHRENIA
por: Rong, Han
Publicado: (2020)

M98. IS THERE A DEVELOPMENTAL TRAUMAGENIC PHENOTYPE OF PSYCHOSIS?
por: Bloomfield, Michael, et al.
Publicado: (2020)

M198. INVESTIGATIONAL DOPAMINE ANTAGONISTS FOR THE TREATMENT OF SCHIZOPHRENIA
Publicado: (2020)

567 Costs and predictors of early discharge and early readmission risk among national cesarean deliveries
por: Panzer, Alexis, et al.
Publicado: (2021)

M200. CLOZAPINE-INDUCED HEPATOTOXICITY: TWO CASE REPORTS
por: Dias, Cintia, et al.
Publicado: (2020)

M106. VIRTUAL-REALITY COGNITIVE TRAINING AND ASSESSMENT IN SCHIZOPHRENIA
por: Porffy, Lilla, et al.
Publicado: (2020)

M215. FACTORS ASSOCIATED WITH CLOZAPINE RESPONSE AND RESISTANCE IN SCHIZOPHRENIA
por: Lee, Jimmy, et al.
Publicado: (2020)

M150. RELATIVES EXPERIENCES OF THE EARLY SIGNS ACTION PLAN
por: Sjöström, Nils, et al.
Publicado: (2020)

M55. STRUCTURAL CHANGES RELEVANT TO MUSICAL DEFICITS IN SCHIZOPHRENIA
por: Sawada, Ken, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_8nvkn1005s88cpdg7845vltc1s